The delisting will have no impact on the company's American
Depositary Shares, which are traded on the Nasdaq, the company
said in a statement.
(Reporting by Radhika Anilkumar in Bengaluru; Editing by Sherry
Jacob-Phillips)
April 4 (Reuters) - Ophthalmology-focused
bio-pharmaceutical company OKYO Pharma said on Tuesday
it has applied to the UK's Financial Conduct Authority and
London Stock Exchange Plc to delist from the LSE's main market.
Disclaimer: The views expressed in this article are those of the author and may not reflect those of Kitco Metals Inc. The author has made every effort to ensure accuracy of information provided; however, neither Kitco Metals Inc. nor the author can guarantee such accuracy. This article is strictly for informational purposes only. It is not a solicitation to make any exchange in commodities, securities or other financial instruments. Kitco Metals Inc. and the author of this article do not accept culpability for losses and/ or damages arising from the use of this publication.